Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2001
10/30/2001US6310057 α-ketoamide multicatalytic protease inhibitors
10/30/2001US6310052 Nitrate esters and their use for neurological conditions
10/30/2001US6310050 Therapeutic use of compounds with β3-agonist activity
10/30/2001US6310042 Derivatives of carbohydrates and compositions containing them
10/30/2001US6309856 Human MAD proteins and uses thereof
10/30/2001US6309825 Analytical and therapeutic agents
10/30/2001US6309663 Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
10/30/2001US6309645 A method of suppressing an immune response in a mammal.
10/30/2001CA2206530C Combined preparation for stimulating hair growth and optionally nail growth and skin regeneration and for preventing or combatting hair loss
10/30/2001CA2052375C Parathyroid hormone derivatives
10/30/2001CA2029863C Compositions and methods for treating viral infections
10/30/2001CA2002833C Interferon-gamma binding proteins
10/28/2001CA2345569A1 Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
10/28/2001CA2345284A1 Blood pressure stabilization during hemodialysis
10/27/2001CA2345180A1 Methods of treating obesity using a neurotensin receptor ligand
10/25/2001WO2001083485A1 Imidazopyrimidine derivatives and triazolopyrimidine derivatives
10/25/2001WO2001079502A2 Vectors for gene therapy
10/25/2001WO2001079480A1 Albumin fusion proteins
10/25/2001WO2001079448A2 Trp8, a transient receptor potential channel expressed in taste receptor cells
10/25/2001WO2001079445A2 Pluripotent cells comprising allogenic nucleus and mitochondria
10/25/2001WO2001079444A2 Albumin fusion proteins
10/25/2001WO2001079443A2 Albumin fusion proteins
10/25/2001WO2001079442A2 Albumin fusion proteins
10/25/2001WO2001079299A1 Enhancement of antibody-mediated immune responses
10/25/2001WO2001079288A2 Cytokine uses; compositions; methods
10/25/2001WO2001079286A2 Compositions and methods for the therapy and diagnosis of breast cancer
10/25/2001WO2001079284A2 Therapeutic compounds and methods for formulating v3, a versican isoform
10/25/2001WO2001079271A1 Albumin fusion proteins
10/25/2001WO2001079269A2 Lipid binding protein 4
10/25/2001WO2001079263A1 Peptide derivatives and medicinal compositions
10/25/2001WO2001079258A1 Albumin fusion proteins
10/25/2001WO2001079249A2 Peptide nucleic acid derivatives with a negative charge, agents and methods for producing them
10/25/2001WO2001079244A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation
10/25/2001WO2001079198A1 Pyrazoles for inhibiting protein kinase
10/25/2001WO2001079197A1 ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ)
10/25/2001WO2001079184A1 Substituted piperazine compounds
10/25/2001WO2001079180A2 5-substituted tetralones as inhibitors of ras farnesyl transferase
10/25/2001WO2001079179A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase
10/25/2001WO2001079173A2 Enamine derivatives as cell adhesion molecules
10/25/2001WO2001079172A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same
10/25/2001WO2001079170A2 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
10/25/2001WO2001079167A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
10/25/2001WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders
10/25/2001WO2001079157A1 Hydrazide and alkoxyamide angiogenesis inhibitors
10/25/2001WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001079153A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
10/25/2001WO2001078784A1 Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same
10/25/2001WO2001078779A2 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease
10/25/2001WO2001078761A2 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors
10/25/2001WO2001078759A1 The use of des-aspartate-angiotensin i as an agent for the treatment and prevention of glomerulosclerosis and renal failure
10/25/2001WO2001078754A2 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof
10/25/2001WO2001078749A1 Novel calcium antagonists
10/25/2001WO2001078743A1 Medical combinations comprising tiotropium and mometasone
10/25/2001WO2001078741A1 Medical combinations comprising tiotropium and budesonide
10/25/2001WO2001078737A1 Medical combinations comprising formoterol and budesonide
10/25/2001WO2001078736A1 Medical combinations comprising tiotropium and rofleponide
10/25/2001WO2001078734A1 Methods of treatment
10/25/2001WO2001078728A1 Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts
10/25/2001WO2001078727A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia
10/25/2001WO2001078726A1 New uses of imidazolylmethyl-pyridines
10/25/2001WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2
10/25/2001WO2001078723A1 Compounds and methods
10/25/2001WO2001078721A1 Aβ42 LOWERING AGENTS
10/25/2001WO2001078720A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol
10/25/2001WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078718A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage
10/25/2001WO2001078712A1 Substituted styryl benzylsulfones for treating proliferative disorders
10/25/2001WO2001078711A2 Pde-v inhibitors for treatment of parkinson's disease
10/25/2001WO2001078709A2 Treatment of neurodegenerative disease
10/25/2001WO2001078703A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity
10/25/2001WO2001078701A2 Method and compositions for preventing hormone induced adverse effects
10/25/2001WO2001078699A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
10/25/2001WO2001078698A2 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
10/25/2001WO2001078692A2 Membrane delivery system
10/25/2001WO2001078680A2 Pharmaceutical compositions comprising fluvastatin
10/25/2001WO2001078677A1 Use of alcohol dehydrogenase inhibitors for cosmetic treatment of keratinous materials
10/25/2001WO2001078654A2 Halogentated 2-amino-3, 4 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
10/25/2001WO2001078649A2 Pharmaceutical curative compound
10/25/2001WO2001078580A2 A method combining inducing hypothermia and administering a therapeutic agent
10/25/2001WO2001051064A8 Ph-regulators against oral stereotypies in equines
10/25/2001WO2001049288A9 Novel compounds and compositions as protease inhibitors
10/25/2001WO2001044512A8 Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression
10/25/2001WO2001044246A8 Bicyclic inhibitors of glycogen synthase kinase 3
10/25/2001WO2001028987A8 Benzylcycloalkyl amines as modulators of chemokine receptor activity
10/25/2001WO2001027113A3 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES
10/25/2001WO2001025238A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases
10/25/2001WO2001023570A3 Methods and compositions relating to sodium channel beta-1a subunits
10/25/2001WO2001022092A3 Method to identify compounds which modulate fra-1 expression fils
10/25/2001WO2001021605A3 Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
10/25/2001WO2001019798A3 Inhibitors of factor xa
10/25/2001WO2001012790A3 Isomerase proteins
10/25/2001WO2001000245A3 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
10/25/2001WO2000061541A8 Pharmaceutical compounds
10/25/2001WO2000056737A9 Calanolides for inhibiting btk
10/25/2001WO2000054761A9 Regulation of phospholipase d activity
10/25/2001WO2000047618A9 HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
10/25/2001WO2000047104A3 Antagonists of hmg1 for treating inflammatory conditions
10/25/2001WO2000011169A3 Human cell signaling proteins (csig)
10/25/2001US20010034447 N-(5-tert-butyl-2-methoxyphenyl)-n'-(4-(1-oxoisoindolin-5-ylox y)penyl)urea as anticarcinogenic agents
1 ... 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 ... 1564